⼩児がん(神経芽腫および⾻⾁腫)に対して光免疫療法が有⽤な可能性があります!

ad

2025-05-20 北海道⼤学

北海道大学の研究チームは、小児がんの神経芽腫と骨肉腫に対して、光免疫療法の有効性を実証しました。GD2抗原を標的とした抗体に光感受性物質を結合させ、特定波長の光を照射することで、がん細胞のみを選択的に死滅させる治療法です。培養細胞とマウスモデルの両方で腫瘍の縮小と組織破壊が確認され、副作用の少ないがん治療法として期待されています。今後は臨床応用に向けた検証が進められます。

⼩児がん(神経芽腫および⾻⾁腫)に対して光免疫療法が有⽤な可能性があります!

<関連情報>

神経芽腫および骨肉腫に対する抗GD2抗体を用いた近赤外光免疫療法 Near-infrared photoimmunotherapy using antiGD2 antibody for neuroblastoma and osteosarcoma

Jimei Zhao, Kohei Nakajima, Masahiro Ueki, Yukayo Terashita, Shinsuke Hirabayashi, Yuko Cho, Mikako Ogawa, Atsushi Manabe
EJC Paediatric Oncology  Available online: 5 May 2025
DOI:https://doi.org/10.1016/j.ejcped.2025.100233

Highlights

  • Near-infrared photoimmunotherapy(NIR-PIT): novel treatment specific to cancer antigen.
  • A preclinical study about NIR-PIT for pediatric cancer.
  • NIR-PIT with antiGD2 antibody was effective for neuroblastoma and osteosarcoma cell.
  • NIR-PIT with antiGD2 antibody was suggested to be effective for neuroblastoma mice model.

Abstract

Introduction

Near-infrared photoimmunotherapy (NIR-PIT) is a novel cancer therapy that specifically targets cancer cells. In NIR-PIT, antibody-photo-absorber-conjugates (APCs), specific for cancer antigens, target cancer cells. APCs that bind to antigens and are irradiated with NIR-light kill targeted cells. NIR-PIT has been clinically applied to head and neck squamous cell carcinoma in Japan, but not to pediatric cancers. Generally, neuroblastoma and osteosarcoma express disialoganglioside (GD2), making NIR-PIT that targets GD2 an additional treatment option.

Methods

Antihuman GD2 monoclonal antibody (clone 3F8) was conjugated with photo-absorber, IRDye 700DX (IR700). A human neuroblastoma cell (SK-N-SH) was used for in vitro and in vivo experiments, whereas human osteosarcoma cells (NOS-10, MG-63) were utilized for in vitro experiments. Microscopy and flow cytometry were used to evaluate cell death after NIR-PIT, and longitudinal measurement of tumor size and histological observation were utilized to assess the effect of NIR-PIT on the xenograft model.

Results

EthD-1 staining after NIR-PIT confirmed the morphological changes (swelling and bleb formation) observed by microscopy and cell death. Flow cytometry verified the significant increase in dead cells after NIR-PIT. Tumor growth in the mice model was significantly inhibited at day 10 of the experiment and destroyed tumor tissue was histologically observed in the PIT-treated mice.

Conclusion

The efficacy of NIR-PIT with antiGD2 antibody for neuroblastoma and osteosarcoma was indicated. Additionally, NIR-PIT efficacy against neuroblastoma was indicated by the mice model in vivo. Therefore, further experiments and more effective protocols should be considered for clinical application.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました